The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

FDA Approves Nasal Spray for Depression. Published Jan 22, 2025 at 5:22 AM EST Updated Jan 22, 2025 at 6:12 AM EST. By . ... the manufacturer Johnson & Johnson said in a press release.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved the nasal spray Spravato as a treatment for severe depression. FDA approves nasal spray drug to treat depression ...

Johnson & Johnson's Spravato was approved to treat a major depressive disorder, or MDD, in adults. The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...

FDA Approves Johnson & Johnson’s Ketamine-Derived ... The U.S. Food & Drug Administration Tuesday approved Johnson & Johnson’s ketamine-derived nasal spray Spravato for ... as a nasal spray ...

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is ...

The nasal spray targets glutamate, the most abundant excitatory neurotransmitter in the brain, according to Johnson & Johnson. If you are interested in taking SPRAVATO, it is recommended you talk ...

FDA approves ketamine nasal spray to treat depression 00:43. The Food and Drug Administration on Tuesday approved a form of ketamine, which is a rapid acting anesthetic that has been used ...

Esketamine, developed by Johnson & Johnson, will be administered as a nasal spray and be used in conjunction with an oral antidepressant. It will be marketed under the brand name Spravato .